Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,833 shares of the biopharmaceutical company’s stock after buying an additional 265 shares during the period. Exchange Traded Concepts LLC’s holdings in Alnylam Pharmaceuticals were worth $902,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the company. Mackenzie Financial Corp raised its position in Alnylam Pharmaceuticals by 94.9% in the 2nd quarter. Mackenzie Financial Corp now owns 36,091 shares of the biopharmaceutical company’s stock valued at $8,770,000 after purchasing an additional 17,576 shares during the last quarter. Algert Global LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $476,000. Creative Planning grew its holdings in shares of Alnylam Pharmaceuticals by 63.2% during the second quarter. Creative Planning now owns 8,034 shares of the biopharmaceutical company’s stock worth $1,952,000 after buying an additional 3,110 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its position in Alnylam Pharmaceuticals by 72.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 596 shares of the biopharmaceutical company’s stock valued at $145,000 after acquiring an additional 250 shares during the period. Finally, Regal Investment Advisors LLC raised its stake in Alnylam Pharmaceuticals by 4.1% during the 2nd quarter. Regal Investment Advisors LLC now owns 3,348 shares of the biopharmaceutical company’s stock valued at $814,000 after acquiring an additional 132 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of recent research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, January 21st. Piper Sandler restated an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. TD Cowen boosted their price target on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Chardan Capital restated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $298.61.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at $3,310,677.18. The trade was a 10.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,372 shares of company stock worth $5,634,205 in the last three months. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $278.99 on Wednesday. The firm’s 50-day moving average is $248.91 and its two-hundred day moving average is $260.56. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The stock has a market capitalization of $35.98 billion, a P/E ratio of -106.48 and a beta of 0.34. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. During the same period in the prior year, the firm earned $1.15 earnings per share. The business’s revenue for the quarter was down 33.3% compared to the same quarter last year. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.